Biofrontera Inc (NAS:BFRI)

Q3 2024 Biofrontera Inc Earnings Call Transcript

Nov 14, 2024 / 03:00 PM GMT

Release Date Price: $0.705 (-15.38%)

Transcript 10-Q8-K

Key Points

Positve

Biofrontera Inc (BFRI) reported a significant increase in the total number of Ameluz tubes ordered, alongside a reduction in costs.
The company improved its FDA label, allowing the use of up to three tubes of Ameluz per treatment, enhancing flexibility for healthcare providers.
Outstanding clinical results were achieved for a new indication, with a high degree of statistical significance in the superficial BCC phase three study.
The launch of the RDO LED XL lamp has been successful, with 105 new lamps installed in the first three quarters of 2024.
Biofrontera Inc (BFRI) has taken control over clinical trials, leading to a reduced transfer price for Ameluz, which is expected to improve profitability.

Negative

Revenues in the third quarter were impacted by delayed shipments due to Hurricane Milton, affecting growth figures.
The net loss for the third quarter of 2024 was $5.7 million, although this was an improvement from the previous year.
Adjusted EBITDA for the third quarter was negative $4.6 million, reflecting higher general and administrative costs.
Legal expenses increased by $0.8 million due to complaints filed by Doa Pharmaceuticals, impacting financial performance.
The company is still not cash flow break-even and anticipates reaching this milestone towards the end of 2025 or early 2026.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BFRI.OQ - Biofrontera Inc
Q3 2024 Biofrontera Inc Earnings Call
Nov 14, 2024 / 03:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in biofrontera's press releases and sec filings. Also, this conference call contains time sensitive information that is accurate only as of the date of this live broadcast. November 14th, 2024. Biofrontera takes no obligations to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law during today's call. There will be references to certain Nongaap financial measures. Biofrontera believes these measures provide useful information for investors yet should not be considered as a substitute for GAAP nor should they be viewed as a substitute for operating

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.